FDA Panel: Heart Closure Device Safety Data Demands Further Study

More study is required to make sense of the adverse event rates associated with two marketed atrial septal defect occluders, a May 24 FDA panel concluded. St. Jude Medical, in particular, should start a new prospective study for its Amplatzer device, the panel recommends.